Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database

[1]  I. Tannock,et al.  Biased Evaluation in Cancer Drug Trials-How Use of Progression-Free Survival as the Primary End Point Can Mislead. , 2022, JAMA oncology.

[2]  T. Petit,et al.  Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database , 2021, Breast.

[3]  M. Mouret-Reynier,et al.  Enrollment of older metastatic breast cancer patients in first-line clinical trials: 9-year experience of the large-scale real-life multicenter French ESME cohort , 2021, Breast Cancer Research and Treatment.

[4]  A. Vincent-Salomon,et al.  Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort , 2021, NPJ breast cancer.

[5]  E. Eisenhauer,et al.  Evolution of the Randomized Clinical Trial in the Era of Precision Oncology. , 2021, JAMA oncology.

[6]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[7]  R. Rouzier,et al.  Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program , 2021, Therapeutic advances in medical oncology.

[8]  S. Mathoulin-Pélissier,et al.  Management and outcome of male metastatic breast cancer in the national multicenter observational research program Epidemiological Strategy and Medical Economics (ESME) , 2020, Therapeutic advances in medical oncology.

[9]  M. Burkard,et al.  Utilizing Data Visualization to Identify Survival and Treatment Differences Between Women With De Novo and Recurrent Metastatic Breast Cancer. , 2020, Clinical breast cancer.

[10]  B. Kiely,et al.  5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) , 2020, Annals of Oncology.

[11]  T. Petit,et al.  Real-world Evaluation of Oral Vinorelbine in the Treatment of Metastatic Breast Cancer: An ESME-MBC Study , 2020, AntiCancer Research.

[12]  S. Mathoulin-Pélissier,et al.  Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016. , 2020, European journal of cancer.

[13]  H. Rugo,et al.  De Novo Versus Recurrent HER2‐Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry , 2019, The oncologist.

[14]  M. Campone,et al.  Real‐life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program , 2019, International journal of cancer.

[15]  T. Petit,et al.  Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort. , 2019, European journal of cancer.

[16]  M. Campone,et al.  Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort , 2019, British Journal of Cancer.

[17]  F. André,et al.  UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO) , 2019, ESMO Open.

[18]  S. Mathoulin-Pélissier,et al.  The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the Epidemiological Strategy and Medical Economics (ESME) , 2019, BMJ Open.

[19]  C. Papadimitriou,et al.  Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study , 2019, BMC Cancer.

[20]  C. Papadimitriou,et al.  Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study , 2019, BMC Cancer.

[21]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[22]  S. Mathoulin-Pélissier,et al.  Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. , 2018, European journal of cancer.

[23]  Les services de l’Etat à La Réunion.  Commission de la transparence , 2018 .

[24]  S. Mathoulin-Pélissier,et al.  Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review. , 2017, Critical reviews in oncology/hematology.

[25]  S. Khozin,et al.  Real-world Data for Clinical Evidence Generation in Oncology. , 2017, Journal of the National Cancer Institute.

[26]  Gary H Lyman,et al.  Untapped Potential of Observational Research to Inform Clinical Decision Making: American Society of Clinical Oncology Research Statement. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  B. Asselain,et al.  Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  S Michiels,et al.  Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  S Michiels,et al.  Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  C. Beauchemin,et al.  Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer , 2014, OncoTargets and therapy.

[31]  H. Rugo,et al.  Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer , 2014, Breast Cancer Research and Treatment.

[32]  M. Schemper,et al.  Estimating the correlation of bivariate failure times under censoring , 2013, Statistics in medicine.

[33]  A. Kesselheim,et al.  Reputation and precedent in the bevacizumab decision. , 2011, The New England journal of medicine.

[34]  James J. Driscoll,et al.  Overall Survival: Still the Gold Standard: Why Overall Survival Remains the Definitive End Point in Cancer Clinical Trials , 2009, Cancer journal.

[35]  A. Onitilo,et al.  Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival , 2009, Clinical Medicine & Research.

[36]  J. Cuzick,et al.  Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer , 2008, British Journal of Cancer.

[37]  M. Buyse,et al.  Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  E. Perez,et al.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.

[39]  S. Hirschfeld,et al.  Oncology drug development: United States Food and Drug Administration perspective. , 2002, Critical reviews in oncology/hematology.

[40]  A. Hartz,et al.  A comparison of observational studies and randomized, controlled trials. , 2000, The New England journal of medicine.

[41]  G. Molenberghs,et al.  The validation of surrogate endpoints in meta-analyses of randomized experiments. , 2000, Biostatistics.

[42]  M Schemper,et al.  A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.

[43]  T. Louis,et al.  Inferences on the association parameter in copula models for bivariate survival data. , 1995, Biometrics.

[44]  S. Barni,et al.  Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials , 2013, Medical Oncology.

[45]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[46]  G. Molenberghs,et al.  Validation of surrogate end points in multiple randomized clinical trials with failure time end points , 2001 .